User profiles for G. Giaccone
 | Giuseppe GiacconeProfessor of Medicine, Weill Cornell University Verified email at med.cornell.edu Cited by 84899 |
Targeting the dynamic HSP90 complex in cancer
J Trepel, M Mollapour, G Giaccone, L Neckers - Nature reviews cancer, 2010 - nature.com
The molecular chaperone heat shock protein 90 (HSP90) has been used by cancer cells to
facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are '…
facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are '…
Cell death independent of caspases: a review
LE Broker, FAE Kruyt, G Giaccone - Clinical Cancer Research, 2005 - AACR
Patterns of cell death have been divided into apoptosis, which is actively executed by specific
proteases, the caspases, and accidental necrosis. However, there is now accumulating …
proteases, the caspases, and accidental necrosis. However, there is now accumulating …
[HTML][HTML] The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the …
This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS)
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …
[HTML][HTML] The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung …
The IASLC Staging and Prognostic Factors Committee has collected a new database of
94,708 cases donated from 35 sources in 16 countries around the globe. This has now been …
94,708 cases donated from 35 sources in 16 countries around the globe. This has now been …
Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1
G Giaccone, RS Herbst, C Manegold… - Journal of Clinical …, 2004 - ascopubs.org
Purpose The purpose of this study was to determine whether the addition of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2
RS Herbst, G Giaccone, JH Schiller… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
… has received honoraria from AstraZeneca to attend advisory boards; Jean Yves Douillard
has received honoraria for participating in advisory boards or symposia; Giuseppe Giaccone …
has received honoraria for participating in advisory boards or symposia; Giuseppe Giaccone …
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
…, EB Haura, M Socinski, K Shirai, H Chen, G Giaccone… - Jama, 2014 - jamanetwork.com
Importance Targeting oncogenic drivers (genomic alterations critical to cancer development
and maintenance) has transformed the care of patients with lung adenocarcinomas. The …
and maintenance) has transformed the care of patients with lung adenocarcinomas. The …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
…, G Klingelschmitt, B Klughammer, G Giaccone - The lancet …, 2010 - thelancet.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
…, MB Beasley, DA Chitale, S Dacic, G Giaccone… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR- and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR- and ALK-directed therapies, addressing …